The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.
The center is an international joint venture established in 2013 between South Korean clinical lab Eone Life Science and California-based Diagnomics.
In 2017, Bionano had $9.5 million in revenues and a net loss of 23.4 million, or $7.66 per share.
The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.
The firm sold more than 4.9 million shares of common stock at $15 per share, raising $73.7 million to expand its commercial operations and grow its technology.
The firm plans to use the proceeds to expands its commercial operations, expand its existing technology, and support the launch of its new platform.
Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
The firm began offering its common shares on Wednesday at $6 per share on the Nasdaq. Gross proceeds from the IPO were $7.1 million.
Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.
The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.
Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.